Eric M. Genden

Eric M. Genden, MD, MHCA, FACS is a United States head and neck cancer surgeon at the Icahn School of Medicine at Mount Sinai and Mount Sinai Health System in New York City. where he serves as the Isidore Friesner Professor and Chairman of Otolaryngology–Head and Neck Surgery and Professor of Neurosurgery and Immunology. According to his biography at Mount Sinai, Genden's professional titles also include Senior Associate Dean for Clinical Affairs, He is Executive Vice President of Ambulatory Surgery, and Director of the Head and Neck Institute at the Mount Sinai Health System.
Education.
Genden received his B.A. degree from Columbia University in 1987 and graduated from Mount Sinai School of Medicine in 1992 where he obtained his MD degree with Distinction in Research, and Harvard University School of Public Health with a Masters in Healthcare Management. His residency training at Washington University and Barnes-Jewish Hospital in St. Louis.
Career.
Genden's expertise is in thyroid, parathyroid surgery, head and neck cancer surgery, and airway reconstruction. Memberships include the New York Head and Neck Society, American Head and Neck Society, American Board of Facial Plastic and Reconstructive Surgery, and the American Broncho-Esophagological Association.
In 2006, Genden performed the first jaw transplant using the patient's jaw and bone marrow.
Genden has authored six textbooks on oncology and microvascular head and neck reconstruction. He published more than 200 peer-reviewed articles and co-authored a chapter about facial transplantation in for Facial Plastic Surgery Clinics of North America. He served as a co-investigator on more than 15 clinical trials.
He received in 1983 the Brooks School and received the Distinguished Brooksian Recipient Award in 2018, and is a contributing editor at the Journal of the American Medical Association's "JAMAevidence".
Research.
A partial list of Genden's research areas include the debate between hemithyroidectomy or total thyroidectomy for well-differentiated stage T2 tumors; he has studied as well as written about palliative care for patients with head and neck cancer; and the role of human papillomavirus status in recurrent and metastatic squamous cell carcinoma of the head and neck.